Hydroxyurea
Hydroxyurea 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Acute Myeloid Leukemia With Gene Mutations。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
5 项
已进入 III/IV 期
19 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- PETHEMA Foundation
- Brown University
- Peking University People's Hospital
- European Organisation for Research and Treatment of Cancer - EORTC
- Children's Hospital Medical Center, Cincinnati
- Paul Szabolcs
- New York University
- Duke University
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
Angola、中国、奥地利、法国、德国、挪威、西班牙、瑞士、Uganda、美国、Nigeria、加拿大
正在招募患者的 Hydroxyurea 研究
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa
III 期招募中AngolaNCT05285917Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
II 期 / III 期招募中中国NCT03793517177Lu-DOTATATE for Recurrent Meningioma
II 期招募中奥地利法国德国挪威NCT06326190Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study
I 期 / II 期招募中UgandaNCT07708714Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
II 期招募中美国NCT01962415mAnaging siCkle CELl disEase Through incReased AdopTion of hydroxyurEa in Nigeria
不适用招募中NigeriaNCT06318143Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
不适用招募中美国加拿大NCT03511118A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial
II 期招募中法国英国NCT06786234Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
II 期 / III 期招募中美国NCT03013998Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
II 期招募中美国NCT06930352Domestication and Implementation of the PEN-Plus Clinical Model in the Zambian Health System
不适用招募中ZambiaNCT07753681Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
I 期 / II 期招募中美国NCT03500731Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies
不适用招募中美国NCT05213572Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease
II 期招募中法国French GuianaNCT06578507A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients
I 期 / II 期招募中挪威NCT06199557Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia
II 期 / III 期招募中加拿大NCT06761560Hydroxyurea Optimisation in Sickle Cell Disease
不适用招募中NigeriaNCT07543289Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
I 期招募中美国NCT06871410Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
II 期招募中中国NCT05870475Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
不适用招募中美国NCT04528355A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
III 期招募中美国BrazilColombiaKenyaNCT06439082Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients
II 期招募中Portugal西班牙NCT07507760T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
I 期 / II 期招募中美国NCT03653338Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
I 期 / II 期招募中美国NCT03128996
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。